CD20 protein

Target entity: CD20 protein
Context triple: [Rituxan, targets, CD20 protein]

• A. Bruton tyrosine kinase
  Bruton tyrosine kinase is a key signaling enzyme in B cells that plays a crucial role in their development and function and is a major therapeutic target in certain blood cancers and autoimmune diseases.
• B. CD38
  CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
• C. programmed death-ligand 1
  Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
• D. Rituxan
  Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
• E. CD4+ T cells
  CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: CD20 protein
Target entity description: CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.

• A. Bruton tyrosine kinase
  Bruton tyrosine kinase is a key signaling enzyme in B cells that plays a crucial role in their development and function and is a major therapeutic target in certain blood cancers and autoimmune diseases.
• B. CD38
  CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
• C. programmed death-ligand 1
  Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
• D. Rituxan
  Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
• E. CD4+ T cells
  CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
• F. None of above. chosen